Quote this publication Share Print


Opinions on drugs - Posted on May 29 2006

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals


Clinical Benefit


The actual medical benefit of this proprietary drug in this indication is significant.

Clinical Added Value


The Transparency Committee considers that PROCORALAN provides a moderate improvement in actual benefit (IAB III) in patients with chronic stable angina with a contraindication or intolerance to beta-blockers and with asymptomatic left ventricular dysfunction (LVEF < 45 %) contraindicating the use of heart rate-decreasing calcium antagonists.

Contact Us

Évaluation des médicaments